Nikos pekiaridis | Lightrocket | Getty image
Pfizer On Monday, the patient said it would end the development of the daily weight loss pill after experiencing the liver damage caused by the drug in the test.
Pfizer spokesman said in a statement that the patient did not experience liver symptoms or side effects. They “recovered quickly” after the patient’s liver enzyme stopped taking pills, which is an oral GLP-1 drug called DanugliPron. This statement has increased the patient’s liver enzyme and often Represents cell damage It is a problem related to other obese drugs in the organs.
The spokesman said the incident occurred in a test that quickly increased the dose of the pills for a short time. According to the release, the Pfizer’s decision on the discontinuance of the drug came out after reviewing the entire information of the information, including all clinical data generated to the date and the recent input of the regulatory institution.
“We are disappointed to stop Danuglipron’s development, but we are dedicated to evaluating and developing promising programs to bring innovative new medicines to patients,” said Chris Boshoff, chief scientific director of Pfizer. He added that the company is still developing other weight loss drugs.
This announcement is added to a series of frustrations to get a piece of a market that is booming in GLP-1 in the company’s bidding. Pfizer is one of some pharmaceutical producers who raced to bring more convenient weight loss medicine to the space dominated by the share of the stock. Ellie Lily and Novo Nordic.
Some Wall Street analysts expect the GLP-1 industry to be worth more than $ 150 billion by the early 2030s. Some analysts say that the oral GLP-1 is worth a total of $ 50 billion, while the injection can explain the remaining injections.
This is not the first of Pfizer’s return with Danuglipron. In December 2023, the company stopped about two pill versions in December 2023 after the patient could not endure the drug in the middle stage.
Pfizer, however, seemed to be confident about the Danuglipron form of Danuglipron once a day in July.
Pfizer said that despite the decision to discard the drug, the study confirmed a specific form and drug that could achieve a major goal and deliver “competition and tolerability” in the late test.
The company also pointed out the ratio. Rising liver enzyme Those who take Danuglipron are consistent with the approved GLP-1 drug, which is based on the safety database of more than 1,400 patients who take the Pfizer Pill.
Pfizer discarded an obesity pill once on June 1, 2023 after the patient taking the drug in the intermediate stage test had a higher liver enzyme level. Investors have been pessimistic about the company’s potential in the GLP-1 space.
Still, there is a pure Other experiments Obesity drugs in the pipeline appear to work differently from the current interfering treatment in the early stages of development. This includes oral GLP-1 once a day in the oral drug that blocks another chapter hormone called GIPR, which entered the second phase of last year, and the first stage test.
Pfizer believes that drugs aimed at GIPR can endure patients more effectively and easily. “There are many applications for GLP-1,” he added.
Pfizer’s danuglipron promotes weight loss by targeting GLP-1, which is also a method of treating Ozempic in the treatment of Wegovy and diabetes of novo nordisk. ELI LILLY’s weight loss swallows and diabetes photographed the Mounjaro Target GLP-1, but activate another chapter hormone called GIP.
The only oral GLP-1 approved by the Food and Drug Administration is Rybelsus of Novo Nordisk. sales 2024.
Pfizer’s announcement will follow the company’s return on Monday as the company regains the foothold and the cobid business has fallen sharply. Pfizer bets on cancer drug pipelines to provide long -term growth, but he emphasized that obesity is a key focus.
